Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China To De-link Indigenous Innovation And Public Procurement Policies - U.S.-China Strategic And Economic Dialogue

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON - In a positive move for the life sciences industry and others conducting business in China, Chinese leaders have agreed to de-link indigenous innovation policies from government procurement, a decision that - if fully implemented - would provide a fairer competitive environment for foreign-invested enterprises in China
Advertisement

Related Content

Forced Technology Transfer Hinders Innovation In China – USTR
PharmAsia News Favorite Stories From 2011
Regulatory And Staffing Challenges For Private Hospitals In Southeast Asia - Private Healthcare World Asia 2011
Regulatory And Staffing Challenges For Private Hospitals In Southeast Asia - Private Healthcare World Asia 2011
European Companies Concerned About Regulatory Environment in China - European Chamber Of Commerce Survey
Public And Private Partnerships Forge Way For China As Innovative Hub - DIA China Conference
Are China's Rising Labor Costs Good For Big Pharma?
Sweating The Little Things: European Companies Call On China to Overhaul Public Procurement System
Chinese President Pledges China Will Not Discriminate Against U.S. Businesses; Broad Healthcare Partnership Unveiled
Chinese President Pledges China Will Not Discriminate Against U.S. Businesses; Broad Healthcare Partnership Unveiled
Advertisement
UsernamePublicRestriction

Register

SC077896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel